Treatment of Recurrent or Progressive Meningiomas With the Radiolabelled Somatostatin Antagonist 177Lu-satoreotide
Status:
Recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
Meningiomas are known to be the most frequent intracranial neoplasms and account for approx.
25-33% of all intracranial tumours.Targeted radionuclide therapy with radiolabelled
somatostatin analogues, also called Peptide Receptor Radionuclide Therapy (PRRT), has proven
to be an effective treatment in metastatic intestinal neuroendocrine tumours and is currently
used in advanced, recurrent or progressive meningiomas with promising results. In this study,
the therapeutic index of a standard and newly developed radiolabelled somatostatin antagonist
will be evaluated and compared in PRRT. In a second step, safety and efficacy of the latter
will be assessed.